FMFiorella Marcheselli

Fiorella Marcheselli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fiorella Marcheselli has a total of 182 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effect of Cytomegalovirus Reactivation on Inflammatory Status and Mortality of Older COVID-19 Patients

    by Robertina Giacconi, Maurizio Cardelli, Francesco Piacenza, Elisa Pierpaoli, Elisabetta Farnocchia, MirKo Di Rosa, Anna Rita Bonfigli, Tiziana Casoli, Francesca Marchegiani, Fiorella Marcheselli, et al.

    Herpesviridae reactivation such as cytomegalovirus (CMV) has been described in severe COVID-19 (COronaVIrusDisease-2019). This study aimed to understand if CMV reactivation in older COVID-19 patients is associated with increased inflammation and in-hospital mortality. In an observational single-center cohort study, 156 geriatric COVID-19 patients were screened for CMV reactivation by RT-PCR. Participants underwent a comprehensive clinical investigation that included medical history, functional evaluation, laboratory tests and cytokine assays (TNF-α, IFN-α, IL-6, IL-10) at hospital admission. In 19 (12.2%) of 156 COVID-19 patients, CMV reactivation was detected. Multivariate Cox regression models showed that in-hospital mortality significantly increased among CMV positive patients younger than 87 years (HR: 9.94, 95% CI: 1.66–59.50). Other factors associated with in-hospital mortality were C-reactive protein (HR: 1.17, 95% CI: 1.05–1.30), neutrophil count (HR: 1.20, 95% CI: 1.01–1.42) and clinical frailty scale (HR:1.54, 95% CI: 1.04–2.28). In patients older than 87 years, neutrophil count (HR: 1.13, 95% CI: 1.05–1.21) and age (HR: 1.15, 95% CI: 1.01–1.31) were independently associated with in-hospital mortality. CMV reactivation was also correlated with increased IFN-α and TNF-α serum levels, but not with IL-6 and IL-10 serum changes. In conclusion, CMV reactivation was an independent risk factor for in-hospital mortality in COVID-19 patients younger than 87 years old, but not in nonagenarians.


  • Open Access

    Sensibility and Specificity of the VitaPCR™ SARS-CoV-2 Assay for the Rapid Diagnosis of COVID-19 in Older Adults in the Emergency Department

    by Francesco Piacenza, Antonio Cherubini, Roberta Galeazzi, Maurizio Cardelli, Robertina Giacconi, Elisa Pierpaoli, Francesca Marchegiani, Fiorella Marcheselli, Rina Recchioni, Tiziana Casoli, et al.

    (1) Background: During the COVID-19 pandemic, rapid and reliable diagnostic tools are needed for detecting SARS-CoV-2 infection in urgent cases at admission to the hospital. We aimed to assess the performances of the rapid molecular VitaPCR™ test (Menarini Diagnostics) in a sample of older adults admitted to the Emergency Department of two Italian hospitals (2) Methods: The comparison between the rapid VitaPCR™ and the RT-PCR was performed in 1695 samples. Two naso-pharyngeal swab samplings from each individual were obtained and processed using the VitaPCR™ and the RT-PCR for the detection of SARS-CoV-2 (3) Results: VitaPCR™ exhibited good precision (<3% CV) and an almost perfect overall agreement (Cohen’s K = 0.90) with the RT-PCR. The limit of detection of the VitaPCR™ was 4.1 copies/µL. Compared to the RT-PCR, the sensitivity, the specificity, and the positive and negative predictive values of VitaPCR™ were 83.4%, 99.9%, 99.2% and 98.3%, respectively (4) Conclusions: The VitaPCR™ showed similar sensitivity and specificity to other molecular-based rapid tests. This study suggests that the VitaPCR™ can allow the rapid management of patients within the Emergency Department. Nevertheless, it is advisable to obtain a negative result by a RT-PCR assay before admitting a patient to a regular ward.


  • Open Access

    Prognostic relevance of normocytic anemia in elderly patients affected by cardiovascular disease

    by Liana Spazzafumo, Fabiola Olivieri, Jacopo Sabbatinelli, Roberta Galeazzi, Rina Recchioni, Fiorella Marcheselli, Paola Tamburrini, Roberto Antonicelli

    Anemia associated with cardiovascular diseases (CVD) is a common condition in older persons. Prevalence and prognostic role of anemia were extensively studied in patients with myocardial infarction (MI) or congestive heart failure (CHF) whereas limited data were available on patients with atrial fibrillation (AF). This study was conducted to assess the clinical prevalence and prognostic relevance of anemia in elderly patients affected by AF and other CVDs. A total of 866 elderly patients (430 men and 436 women, age: 65−98 years, mean age: 85 ± 10 years) were enrolled. Among these patients, 267 patients had acute non-ST-segment elevation MI (NSTEMI), 176 patients had acute CHF, 194 patients had acute AF and 229 patients were aged-matched healthy persons (CTR). All parameters were measured at the hospital admission and cardiovascular mortality was assessed during twenty-four months of follow-up. The prevalence of anemia was higher in NSTEMI, CHF and AF patients compared to CTR subjects (50% vs. 15%, P < 0.05), with normocytic anemia being the most prevalent type (90%). Adjusted mortality risk was higher in anemic patient versus non-anemic patient in all the groups of patients [NSTEMI: hazard ratio (HR) = 1.81, 95% CI: 1.06−2.13; CHF: HR = 2.49, 95% CI: 1.31−4.75; AF: HR = 1.98, 95% CI: 1.01−3.88]. Decreased hemoglobin levels ( P = 0.001) and high reticulocyte index (P = 0.023) were associated with higher mortality in CVD patients. The significant associations between CVD and anemia and the prognostic relevance of anemia for elderly patients with CVD were confirmed in this study. The presence of anemia in AF patients is associated with a two-fold increased mortality risk compared with non-anemic AF patients. Low hemoglobin and high reticulocyte count independently predict mortality in elderly patients with CVD.


  • Open Access

    Small extracellular vesicles deliver miR‐21 and miR‐217 as pro‐senescence effectors to endothelial cells

    by Emanuela Mensà, Michele Guescini, Angelica Giuliani, Maria Giulia Bacalini, Deborah Ramini, Giacomo Corleone, Manuela Ferracin, Gianluca Fulgenzi, Laura Graciotti, Francesco Prattichizzo, et al.

    The role of epigenetics in endothelial cell senescence is a cutting‐edge topic in ageing research. However, little is known of the relative contribution to pro‐senescence signal propagation provided by microRNAs shuttled by extracellular vesicles (EVs) released from senescent cells. Analysis of microRNA and DNA methylation profiles in non‐senescent (control) and senescent (SEN) human umbilical vein endothelial cells (HUVECs), and microRNA profiling of their cognate small EVs (sEVs) and large EVs demonstrated that SEN cells released a significantly greater sEV number than control cells. sEVs were enriched in miR‐21‐5p and miR‐217, which target DNMT1 and SIRT1. Treatment of control cells with SEN sEVs induced a miR‐21/miR‐217‐related impairment of DNMT1‐SIRT1 expression, the reduction of proliferation markers, the acquisition of a senescent phenotype and a partial demethylation of the locus encoding for miR‐21. MicroRNA profiling of sEVs from plasma of healthy subjects aged 40–100 years showed an inverse U‐shaped age‐related trend for miR‐21‐5p, consistent with senescence‐associated biomarker profiles. Our findings suggest that miR‐21‐5p/miR‐217 carried by SEN sEVs spread pro‐senescence signals, affecting DNA methylation and cell replication.


  • Physical activity and progenitor cell-mediated endothelial repair in chronic heart failure: Is there a role for epigenetics?

    by Rina Recchioni, Fiorella Marcheselli, Roberto Antonicelli, Raffaella Lazzarini, Emanuela Mensà, Roberto Testa, Antonio Domenico Procopio, Fabiola Olivieri


  • Open Access

    Anti-TNF-α treatment modulates SASP and SASP-related microRNAs in endothelial cells and in circulating angiogenic cells

    by Francesco Prattichizzo, Angelica Giuliani, Rina Recchioni, Massimiliano Bonafè, Fiorella Marcheselli, Sabrina De Carolis, Anna Campanati, Katia Giuliodori, Maria Rita Rippo, Francesca Brugè, et al.

    Endothelial cell senescence is characterized by acquisition of senescence-associated secretory phenotype (SASP), able to promote inflammaging and cancer progression. Emerging evidence suggest that preventing SASP development could help to slow the rate of aging and the progression of age-related diseases, including cancer. Aim of this study was to evaluate whether and how adalimumab, a monoclonal antibody directed against tumor necrosis factor-α (TNF-α), a major SASP component, can prevent the SASP. A three-pronged approach has been adopted to assess the if adalimumab is able to: i) modulate a panel of classic and novel senescence- and SASP-associated markers (interleukin [IL]-6, senescence associated-β-galactosidase, p16/Ink4a, plasminogen activator inhibitor 1, endothelial nitric oxide synthase, miR-146a-5p/Irak1 and miR-126-3p/Spred1) in human umbilical vein endothelial cells (HUVECs); ii) reduce the paracrine effects of senescent HUVECs’ secretome on MCF-7 breast cancer cells, through wound healing and mammosphere assay; and iii) exert significant decrease of miR-146a-5p and increase of miR-126-3p in circulating angiogenic cells (CACs) from psoriasis patients receiving adalimumab in monotherapy.


  • Nutritional Modulators of Cellular Senescence In Vitro

    by Mauro Provinciali, Elisa Pierpaoli, Francesco Piacenza, Robertina Giacconi, Laura Costarelli, Andrea Basso, Rina Recchioni, Fiorella Marcheselli, Dorothy Bray, Khadija Benlhassan, et al.


  • Open Access

    MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: relationship with type 2 diabetes complications

    by Fabiola Olivieri, Liana Spazzafumo, Massimiliano Bonafè, Rina Recchioni, Francesco Prattichizzo, Fiorella Marcheselli, Luigina Micolucci, Emanuela Mensà, Angelica Giuliani, Gabriele Santini, et al.

    MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: relationship with type 2 diabetes complications


  • Open Access

    Age- and glycemia-related miR-126-3p levels in plasma and endothelial cells

    by Fabiola Olivieri, Massimiliano Bonafè, Liana Spazzafumo, Mirko Gobbi, Francesco Prattichizzo, Rina Recchioni, Fiorella Marcheselli, Lucia La Sala, Roberta Galeazzi, Maria Rita Rippo, et al.

    Circulating miR-126-3p levels were determined in 136 healthy subjects (CTRs) aged 20-90 years and 193 patients with type-2 diabetes mellitus (T2DMs) aged 40-80 years, to explore the combined effect of age and glycemic state on miR-126-3p expression. Moreover, intra/extracellular miR-126-3p levels were measured in human endothelial cells (HUVECs) undergoing senescence under normo/hyper-glycemic conditions. Plasma miR-126-3p was significantly higher in the oldest compared with the youngest CTRs ( 75 years; relative expression: 0.27±0.29 vs. 0.48±0.39, p=0.047). Age-based comparison between CTRs and T2DM demonstrated significantly different miR-126-3p levels only in the oldest (0.48±0.39 vs. 0.22±0.23, p<0.005). After multiple adjustments, miR-126-3p levels were seen to be lower in patients with poor glycemic control, compared with age-matched CTRs. The age-related increase in plasma miR-126-3p found in CTRs was paralleled by a 5/6-fold increase in intra/extracellular miR-126-3p in in vitro-cultured HUVECs undergoing senescence. Notably, significant down- regulation of SPRED-1 protein, a validated miR-126-3p target, was found in senescent HUVECs. Moreover, miR-126-3p expression was down-regulated in intermediate-age HUVECs grown in high-glucose medium until senescence. Aging/senescence-associated miR-126-3p up-regulation is likely a senescence-associated compensatory mechanism that is blunted when endothelial cells are exposed to high glucose levels, a phenomenon that probably occurs in vivo in T2DM patients.


  • Admission levels of circulating miR-499-5p and risk of death in elderly patients after acute non-ST elevation myocardial infarction

    by Fabiola Olivieri, Roberto Antonicelli, Liana Spazzafumo, Gabriele Santini, Maria Rita Rippo, Roberta Galeazzi, Simona Giovagnetti, Yuri D'ALessandra, Fiorella Marcheselli, Maurizio C. Capogrossi, et al.